Xuanjing Biologics Completes Initial Tranche of Pre-A Financing to Advance Lead siRNA Candidate RG002C0106 and Extrahepatic Delivery Platform

Recently, Rigerna announced the completion of the first closing of its Pre-A round of financing. The first-stage funds were invested by Jinyifu Xinxin and others. This market-oriented financing will be used to rapidly advance the clinical research of its core product RG002C0106, as well as the continued development of extrahepatic delivery technology and drug pipelines. The company will complete the subsequent stages of this round of financing in a short period of time.

Since its establishment in 2022, Rigerna has rapidly built three proprietary technology platforms for small nucleic acid drug development—RIHOST® (design and screening technology), RICMO® (chemical modification technology), and LICOD® (in vivo delivery technology)—breaking through key industry bottlenecks. This has enabled a multi-dimensional technological layout ranging from liver-targeted to non-liver tissue delivery, achieving several breakthrough advancements. The company’s leading pipeline is an siRNA drug targeting complement C3, which shows excellent development potential for high-incidence indications with significant unmet clinical needs as well as various rare diseases. Currently in Phase I clinical trials, the drug is about to enter Phase II clinical trials and is expected to become the best-in-class and one of the world's first marketed siRNA drugs targeting C3. Additionally, Rigerna has developed globally actionable delivery technologies for various extrahepatic tissues, including kidneys, skeletal muscles, adipose tissue, heart, central nervous system, lungs, and eyes. Notably, its kidney tissue delivery technology is at the global forefront. Based on these liver and extrahepatic tissue delivery technologies, the company has established a robust pipeline of liver-targeted and extrahepatic tissue-targeted drugs, advancing preclinical and clinical development through multiple approaches.